Zivo Bioscience Reports Revenue Growth to $53,400 but Faces $1.6M Net Loss in Q2 2025

Zivo Bioscience, Inc. reported its financial results for the second quarter of 2025, revealing a total revenue of $53,400, a significant increase from zero revenue in the same period last year. The company attributed this growth to the sale of its dried algal biomass product as a food ingredient. However, despite this revenue generation, Zivo recorded a net loss of $1,640,232 for the quarter, a notable reduction from the $8,236,368 loss reported in the second quarter of 2024. For the first half of 2025, the company’s total revenue reached $53,400, compared to $35,720 in the prior year, while the net loss for the six months was $5,851,418, down from $9,514,854.

The company’s financial position showed a decline in total assets, which decreased to $703,327 as of June 30, 2025, from $1,643,122 at the end of 2024. Current liabilities increased significantly to $2,959,588, up from $2,041,823, primarily due to higher accounts payable and accrued liabilities. Zivo's accumulated deficit also widened to $142,817,969, reflecting ongoing operational challenges. The company’s cash reserves dwindled to $9,823, down from $1,542,442 at the end of 2024, raising concerns about its liquidity and ability to fund operations.

Operationally, Zivo has made strategic moves, including entering into seventeen Exchange Agreements with investors, which resulted in the issuance of 146,660 shares of common stock. This initiative aimed to cancel certain revenue-sharing agreements in exchange for equity, thereby reducing future cash obligations. The company also reported a significant reduction in general and administrative expenses, which fell to approximately $1.2 million in the second quarter of 2025 from $6.0 million in the same quarter of 2024. This decrease was largely due to lower labor-related costs and professional services expenses.

Looking ahead, Zivo Bioscience faces substantial challenges, including the need for additional funding to sustain operations. The company has indicated that it requires approximately $6 million over the next 12 months to cover basic operations, excluding research and development initiatives. Management has expressed concerns about its ability to continue as a going concern, emphasizing the necessity of securing further financing through equity or debt. The company’s future performance will depend on its ability to generate sufficient revenue from its product offerings and manage its operational costs effectively.